Virus infection inhibitor and virus infection inhibiting product

Abstract

The present invention provides a viral infection inhibitor capable of exhibiting an excellent viral infection inhibitory effect. The viral infection inhibitor of the present invention is characterized by including a compound having a salt of a sulfonic acid group and an organic acid, The organic acid preferably has a solubility of 20 g / L or less in water at 25°C, and therefore, the viral infection inhibitor has an excellent viral infection inhibitory effect against both enveloped viruses and non-enveloped viruses, and exhibits the viral infection inhibitory effect against various types of viruses.

Description

Virus infection inhibitors and virus infection inhibitor products

[0001] The present invention relates to a virus infection inhibitor and a virus infection inhibitor product.

[0002] In recent years, in addition to the seasonal influenza virus epidemic, the novel coronavirus (COVID-19) has become a global pandemic.

[0003] Furthermore, highly pathogenic avian influenza viruses have mutated and been confirmed to infect humans, and there are also concerns about the SARS virus, which has an extremely high mortality rate, so anxiety about viruses is only increasing.

[0004] To address these problems, Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by weight or more of a sulfonic acid surfactant per 100 parts by weight of synthetic resin.

[0005] JP 2016-128395 A

[0006] However, the above-mentioned antiviral synthetic resin composition merely contains a sulfonic acid surfactant in a synthetic resin, and the sulfonic acid surfactant does not have sufficient antiviral properties (viral infection inhibitory effect), and therefore a virus infection inhibitor with excellent virus infection inhibitory effect is desired.

[0007] The present invention provides a virus infection inhibitor that can exert an excellent virus infection inhibitory effect.

[0008] The viral infection inhibitor of the present invention is characterized by comprising a compound having a salt of a sulfonic acid group and an organic acid.

[0009] The viral infection-inhibiting product of the present invention is characterized by comprising: a base material; and the viral infection-inhibiting agent contained in the base material.

[0010] The viral infection inhibitor of the present invention contains a compound having a salt of a sulfonic acid group and an organic acid, and therefore has an excellent viral infection inhibitory effect against both enveloped and non-enveloped viruses, and exhibits a viral infection inhibitory effect against various types of viruses.

[0011] The viral infection inhibitor of the present invention contains, as active ingredients, a compound having a salt of a sulfonic acid group and an organic acid.

[0012] [Compounds Having a Salt of a Sulfonic Acid Group] Compounds having a salt of a sulfonic acid group have a salt of a sulfonic acid group in the molecule. The compounds having a salt of a sulfonic acid group are salts of a sulfonic acid group (-SO3X: ​​X is a metal element or NH4 + The compound having a salt of a sulfonic acid group exhibits an inhibitory effect against viral infection due to the molecular structure containing the salt. The compound having a salt of a sulfonic acid group exhibits an excellent inhibitory effect against viral infection, particularly against enveloped viruses. The compound having a salt of a sulfonic acid group may have a carboxy group (-COOH), a thiol group (-SH), and a hydroxy group (-OH).

[0013] The salt of the sulfonic acid group is not particularly limited, and examples thereof include sodium salt, calcium salt, ammonium salt, magnesium sulfonate, and barium sulfonate, with sodium salt being preferred.

[0014] The compound having a salt of a sulfonic acid group is preferably an organic compound. In the present invention, an organic compound refers to a compound that contains at least one carbon atom (preferably two or more) and a carbon-hydrogen bond (C—H bond) in the molecule.

[0015] When the compound having a salt of a sulfonic acid group is an organic compound, the affinity with the organic acid described below is improved, the compound having a salt of a sulfonic acid group and the organic acid become closer, the interaction between the compound having a salt of a sulfonic acid group and the organic acid is improved, and the viral infection-inhibiting effect against both non-enveloped viruses and enveloped viruses is improved.

[0016] Furthermore, when the virus infection inhibitor is used by adhering it to the surface of resin particles, if the compound having a salt of a sulfonic acid group is an organic compound, the compound having a salt of a sulfonic acid group has hydrophobicity in the organic chain portion (hydrophobic portion) represented by the carbon-hydrogen bond portion. In the compound having a salt of a sulfonic acid group, the organic chain portion has excellent affinity with the resin particles, while the salt of the sulfonic acid group, which has a lower affinity with the resin particles than the organic chain portion, tends to face outward, allowing the virus infection inhibitor to be more effectively exerted.

[0017] The compound having a sulfonic acid group salt preferably has an aromatic ring. When the compound having a sulfonic acid group salt has an aromatic ring, the affinity with the organic acid is improved, the compound having a sulfonic acid group salt and the organic acid are brought closer together, the interaction between the compound having a sulfonic acid group salt and the organic acid is improved, and the viral infection-inhibiting effect against both enveloped and non-enveloped viruses is improved.

[0018] When a viral infection inhibitor or the compound having a salt of a sulfonic acid group that constitutes it is used by adhering it to the surface of resin particles, if the compound having a salt of a sulfonic acid group has an aromatic ring, the affinity between the aromatic ring and the synthetic resin that constitutes the resin particles allows the compound having a salt of a sulfonic acid group to remain firmly attached to the surface of the resin particles, preventing the compound having a salt of a sulfonic acid group from falling off, and allowing the viral infection inhibitor to maintain its excellent viral infection inhibitory effect over a long period of time.

[0019] The aromatic ring may be a monocyclic aromatic ring, or may be a condensed aromatic ring formed by condensing monocyclic aromatic rings. The aromatic ring is not particularly limited, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, a biphenyl, and a phenoxyphenyl, with a benzene ring and a naphthalene ring being preferred. The aromatic ring has one or more hydrogen atoms abstracted from either the aromatic ring or the condensed aromatic ring, and is bonded to other atoms by a covalent bond.

[0020] In the compound having a salt of a sulfonic acid group, the sulfonic acid group is preferably directly or indirectly bonded to an aromatic ring, more preferably directly bonded to the aromatic ring. The affinity between the aromatic ring of the compound having a salt of a sulfonic acid group and the organic acid brings the compound having a salt of a sulfonic acid group and the organic acid closer, thereby improving the synergistic effect between the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid, and thereby improving the viral infection inhibitory effect against both enveloped viruses and non-enveloped viruses.

[0021] In a compound having a salt of a sulfonic acid group, when the salt of the sulfonic acid group is indirectly bonded to an aromatic ring, the salt of the sulfonic acid group is preferably bonded to the aromatic ring via an alkylene group (preferably a methylene group or an ethylene group) having 1 to 4 carbon atoms. While maintaining the affinity between the aromatic ring in the compound having a salt of a sulfonic acid group and the organic acid, the alkylene group causes the salt of the sulfonic acid group to be appropriately spaced from the aromatic ring, allowing the salt of the sulfonic acid group to be oriented in a more exposed state, and the virus infection inhibitor exhibits an excellent virus infection inhibitory effect.

[0022] The compound having a salt of a sulfonic acid group is not particularly limited as long as it has one or more salts of a sulfonic acid group in the molecule, and examples thereof include linear alkylbenzene sulfonates, α-olefin sulfonates, alkyl diphenyl ether sulfonates, polyoxyalkylene alkyl ether sulfates, and polymers having a salt of a sulfonic acid group in the side chain of a linear polymer.

[0023] Examples of linear alkylbenzenesulfonates include sodium dodecylbenzenesulfonate, calcium dodecylbenzenesulfonate, ammonium dodecylbenzenesulfonate, magnesium dodecylbenzenesulfonate, barium dodecylbenzenesulfonate, sodium tridecylbenzenesulfonate, ammonium tridecylbenzenesulfonate, sodium tetradecylbenzenesulfonate, and ammonium tetradecylbenzenesulfonate, with sodium dodecylbenzenesulfonate being preferred.

[0024] The number of carbon atoms in the alkyl group of the linear alkylbenzenesulfonate is preferably 10 or more, more preferably 11 or more, and still more preferably 12 or more. The number of carbon atoms in the alkyl group of the linear alkylbenzenesulfonate is preferably 25 or less, more preferably 20 or less, and still more preferably 18 or less. When the number of carbon atoms in the alkyl group is within the above range, the affinity between the hydrophobic portion derived from the alkyl group and the organic acid brings the compound having a salt of a sulfonic acid group and the organic acid closer together, thereby improving the synergistic effect between the salt of the sulfonic acid group in the compound having a salt of a sulfonic acid group and the organic acid, and thereby improving the viral infection-inhibiting effect against both enveloped and non-enveloped viruses.

[0025] Examples of α-olefin sulfonates include C12 to C18 sodium olefin sulfonate, C12 to C18 calcium olefin sulfonate, C12 to C18 ammonium olefin sulfonate, C12 to C18 magnesium olefin sulfonate, and C12 to C18 barium olefin sulfonate, with C14 sodium tetradecene sulfonate being preferred.

[0026] The number of carbon atoms of the α-olefin in the α-olefin sulfonate is preferably 12 or more, and more preferably 14 or more. The number of carbon atoms of the α-olefin in the α-olefin sulfonate is preferably 22 or less, and more preferably 18 or less. When the number of carbon atoms of the α-olefin is within the above range, the affinity between the organic acid and the hydrophobic portion derived from the α-olefin chain of the compound having a salt of a sulfonic acid group brings the compound having a salt of a sulfonic acid group and the organic acid closer together, thereby improving the synergistic effect between the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid, and thereby improving the viral infection-inhibiting effect against both enveloped viruses and non-enveloped viruses.

[0027] Examples of alkyl diphenyl ether sulfonates include sodium salts, calcium salts, ammonium salts, magnesium salts, and barium salts of alkyl phenyl ethers having an alkyl group of C6 to C18, with sodium dodecyl diphenyl ether sulfonate having an alkyl group of C12 being preferred.

[0028] The number of carbon atoms in the alkyl group of the alkyl diphenyl ether sulfonate is preferably 8 or more, and more preferably 10 or more. The number of carbon atoms in the alkyl group of the alkyl diphenyl ether sulfonate is preferably 24 or less, and more preferably 18 or less. When the number of carbon atoms in the alkyl group is within the above range, the affinity between the organic acid and the hydrophobic portion derived from the alkyl group of the compound having a salt of a sulfonic acid group brings the compound having a salt of a sulfonic acid group and the organic acid closer together, thereby improving the synergistic effect between the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid, and thereby improving the viral infection-inhibiting effect against both enveloped viruses and non-enveloped viruses.

[0029] In the polymer having a salt of a sulfonic acid group in the side chain of a linear polymer, the linear polymer is not particularly limited, and for example, vinyl polymers, polyesters, and polyurethanes are preferred, with vinyl polymers being preferred.

[0030] The polymer having a salt of a sulfonic acid group in the side chain of a linear polymer is not particularly limited, and examples thereof include a polymer containing a styrene sulfonate component, a styrene sulfonate homopolymer, a styrene-styrene sulfonate copolymer, a sulfonate of a compound obtained by sulfonating the benzene ring of polystyrene, and a sulfonate of a compound obtained by sulfonating the benzene ring of a polymer containing a styrene component.

[0031] Furthermore, the polymer having a salt of a sulfonic acid group in the side chain of the linear polymer is preferably a homopolymer or copolymer of a monomer having a salt of a sulfonic acid group. Examples of the monomer having a salt of a sulfonic acid group include sodium p-styrenesulfonate, sodium m-styrenesulfonate, sodium o-styrenesulfonate, calcium p-styrenesulfonate, calcium m-styrenesulfonate, calcium o-styrenesulfonate, ammonium p-styrenesulfonate, ammonium m-styrenesulfonate, ammonium o-styrenesulfonate, sodium naphthalenesulfonate, and calcium naphthalenesulfonate. Sodium styrenesulfonate is preferred, and sodium p-styrenesulfonate is more preferred due to its less steric hindrance in reactivity with viruses.

[0032] The monomer having a salt of a sulfonic acid group may form a copolymer with another monomer. Examples of copolymerizable monomers include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylic acid, sodium acrylate, methacrylic acid, maleic acid, fumaric acid, maleic anhydride, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, xylene sulfonic acid, vinyl pyridine, vinyl sulfonic acid, vinyl alcohol, methyl methacrylate, sodium methacrylate, and hydroxyethyl methacrylate, with styrene being preferred.

[0033] A polymer having a salt of a sulfonic acid group in the side chain of a linear polymer can be produced by a general method, such as a method of radically polymerizing a monomer having a salt of a sulfonic acid group, a method of radically polymerizing a monomer having a salt of a sulfonic acid group and a monomer copolymerizable with this monomer, or a method of neutralizing the sulfonic acid of a polymer containing a monomer component having a salt of a sulfonic acid group with an alkali (e.g., sodium hydroxide, calcium hydroxide, potassium hydroxide, ammonium hydroxide, etc.).

[0034] [Organic Acid] The viral infection inhibitor contains an organic acid. By containing an organic acid, the viral infection inhibitor can promote the release of a salt of a sulfonic acid group in a compound having a salt of a sulfonic acid group, thereby improving the viral infection inhibitory effect against non-enveloped viruses, and thereby improving the viral infection inhibitory effect against enveloped viruses and non-enveloped viruses.

[0035] Furthermore, compounds having a salt of a sulfonic acid group can weaken the capsid (protein shell) of non-enveloped viruses, thereby improving the inhibitory effect of organic acids on viral infection with non-enveloped viruses.

[0036] In this way, the viral infection inhibitor contains a compound having a salt of a sulfonic acid group and an organic acid, thereby improving the viral infection inhibitory effect against enveloped viruses and non-enveloped viruses.

[0037] The organic acid may be any organic compound capable of promoting the release of salts of some or all of the sulfonic acid groups in a compound having a salt of a sulfonic acid group, and may be a polymer. The organic acid has a carboxy group (-COOH), a sulfonic acid group (-SOH), a thiol group (-SH), or a hydroxy group (-OH) in its molecule, and may have only one of these functional groups or may have multiple types of functional groups. The organic acid preferably has a carboxy group, since this can more effectively maintain or promote the release of salts of some or all of the sulfonic acid groups in a compound having a salt of a sulfonic acid group, thereby further improving the viral infection inhibitory effect against enveloped viruses and non-enveloped viruses.

[0038] The organic acid preferably has a plurality of functional groups selected from the group consisting of a carboxy group (-COOH), a sulfonic acid group (-SOH), a thiol group (-SH), and a hydroxy group (-OH) in the molecule, and more preferably has a plurality of carboxy groups. When the organic acid has a plurality of such functional groups, it is possible to more reliably maintain or promote the release of salts of some or all of the sulfonic acid groups in the compound having a salt of a sulfonic acid group, thereby further improving the viral infection inhibitory effect against enveloped viruses and non-enveloped viruses. It is preferable that the organic acid does not contain a salt of a sulfonic acid group.

[0039] The organic acid is not particularly limited as long as it has a carboxy group (-COOH), a sulfonic acid group (-SO3H), a thiol group (-SH), or a hydroxy group (-OH) in the molecule, and examples thereof include adipic acid (solubility: 14 g / L), benzoic acid (solubility: 3.4 g / L), lauric acid (solubility: 0 g / L), azelaic acid (solubility: 2.4 g / L), sebacic acid (solubility: 0.25 g / L), and dodecamethylolpropanediol (solubility: 0.5 g / L). Dibenzofuran (solubility: 0 g / L), fumaric acid (solubility: 6.3 g / L), phthalic acid (solubility: 7.2 g / L), isophthalic acid (solubility: 0.13 g / L), terephthalic acid (solubility: 0.017 g / L), methylenedisalicylic acid (solubility: 0 g / L), cis-Δ4-tetrahydrophthalic acid (solubility: 0 g / L), caproic acid (solubility: 11 g / L), enanthic acid (solubility: 2.4 g / L), capric acid (solubility: 11 g / L), benzofuran ... Acid (solubility: 0.68 g / L), Pelargonic acid (solubility: 0.28 g / L), Capric acid (solubility: 0.15 g / L), Lauric acid (solubility: 0.0048 g / L), Myristic acid (solubility: 0 g / L), Palmitic acid (solubility: 0 g / L), Stearic acid (solubility: 0 g / L), Myristoleic acid (solubility: 0 g / L), Oleic acid (solubility: 0 g / L), Ricinoleic acid (solubility: 0 g / L), salicylic acid (solubility: 2.0 g / L), gallic acid hydrate (solubility: 11 g / L), benzilic acid (solubility: 1.4 g / L), 4-aminobenzoic acid (solubility: 6 g / L), triglycolaminic acid (solubility: 1.3 g / L), polyacrylic acid (solubility: 250 g / L or more), etc. are preferred, with adipic acid, fumaric acid, phthalic acid, and benzoic acid being more preferred. The organic acids may be used alone or in combination of two or more. The solubility shown in parentheses is the solubility of the organic acid in water at 25°C.

[0040] The solubility of the organic acid in water at 25°C is preferably 20 g / L or less, and more preferably 18 g / L or less. When the solubility of the organic acid in water at 25°C is 20 g / L or less, the hydrophobicity of the compound having a salt of a sulfonic acid group is improved, which improves the affinity with the organic acid, bringing the compound having a salt of a sulfonic acid group and the organic acid closer together. This improves the synergistic effect between the salt of the sulfonic acid group of the compound having a salt of a sulfonic acid group and the organic acid, thereby improving the viral infection inhibitory effect against both enveloped and non-enveloped viruses. The solubility of the organic acid in water at 25°C refers to the mass of the organic acid that dissolves in 1 L of water.

[0041] The solubility of the organic acid in water at 25° C. is preferably 0.1 g / L or more, and more preferably 1 g / L or more. When the organic acid has a solubility in water at 25° C. of 0.1 g / L or more, when the organic acid comes into contact with an aqueous protein solution containing viruses, such as saliva or sputum, the release of the salt of the sulfonic acid group in the compound having the salt of the sulfonic acid group is promoted, thereby improving the viral infection-inhibiting effect against non-enveloped viruses.

[0042] The organic acid preferably has a pKa at 25°C of 5.5 or less, more preferably 4.6 or less, and even more preferably 3.8 or less. When the pKa at 25°C of the organic acid is 5.5 or less, the synergistic effect of the salt of the sulfonic acid group and the organic acid improves the viral infection inhibitory effect against enveloped viruses. When the pKa at 25°C is 3.8 or less, the release of the salt of the sulfonic acid group is further promoted, causing protein denaturation by protons, thereby improving the viral infection inhibitory effect against not only enveloped viruses but also non-enveloped viruses. The pKa of the organic acid refers to a value measured by titration at 25°C. Specifically, the pKa can be determined by titrating the organic acid and sodium hydroxide at 25°C and measuring the pH at 25°C at the half-equivalent point (the point at which half the amount required for complete neutralization is added dropwise).

[0043] When the organic acid is a polymer, the weight-average molecular weight of the organic acid is preferably at least 3000, preferably at least 5000, more preferably at least 10000, and even more preferably at least 100000. When the weight-average molecular weight of the organic acid is at least 3000, whitening and yellowing of the virus infection inhibitor can be reduced, and when the virus infection inhibitor is attached to the surface of a substrate, the virus infection inhibitory effect can be more effectively exerted without impairing the appearance of the substrate, and the number of adsorption points with viruses per molecule of the organic acid increases, strengthening the interaction between the organic acid and viruses and improving the virus infection inhibitory effect of the virus infection inhibitor.

[0044] The weight-average molecular weight of the organic acid is preferably not more than 1,000,000, more preferably not more than 900,000, more preferably not more than 800,000, and still more preferably not more than 500,000. When the weight-average molecular weight of the organic acid is 1,000,000 or less, yellowing of the virus infection inhibitor can be reduced, and when the virus infection inhibitor is attached to the surface of a substrate, the virus infection inhibitory effect can be more effectively exerted without impairing the appearance of the substrate, and the coagulation tendency of the organic acid is reduced, resulting in a form in which the organic acid and viruses can easily interact with each other, improving the virus infection inhibitory effect of the virus infection inhibitor.

[0045] In the present invention, the weight average molecular weight of the polymer is a value measured by GPC (gel permeation chromatography) and converted into polystyrene.

[0046] For example, the measurement can be performed using the following measuring device and conditions: Gel permeation chromatograph: Waters Corporation, trade name "2690 Separations Model" Column: Showa Denko K.K., trade name "GPC KF-806L" Detector: differential refractometer Sample flow rate: 1 mL / min Column temperature: 40° C. Eluent: THF

[0047] The organic acid may be in a particulate form. The D90 particle size of the particulate organic acid is preferably 2 μm or more, more preferably 2.5 μm or more, more preferably 3 μm or more, and more preferably 3.5 μm or more. The D90 particle size of the organic acid is preferably 25 μm or less, more preferably 22 μm or less, more preferably 20 μm or less, more preferably 18 μm or less, more preferably 16 μm or less, more preferably 14 μm or less, and more preferably 12 μm or less. When the D90 particle size is 2 μm or more, the surface area of ​​the entire organic acid is reduced, the aggregability of the virus infection inhibitor is reduced, and the organic acid and viruses are in a form that facilitates interaction, thereby improving the virus infection inhibitory effect of the virus infection inhibitor. When the D90 particle size is 25 μm or less, aggregation of the virus infection inhibitor is prevented and the surface area is increased, facilitating contact with viruses, thereby improving the virus infection inhibitory effect of the virus infection inhibitor, and whitening due to crystallization of the organic acid caused by interactions between functional groups [carboxy group (-COOH), sulfonic acid group (-SOH), thiol group (-SH), and / or hydroxy group (-OH)] possessed by the organic acid can be largely prevented.

[0048] As described below, the D90 particle size of a particulate organic acid is the particle size (90% cumulative particle size) at which the cumulative frequency (cumulative from particles with small particle sizes) in a volume-based particle size distribution measured by laser scattering method is 90%. The D90 particle size of the organic acid is preferably adjusted to 2 to 25 μm, and the particle size of large particles in the organic acid is adjusted to a predetermined range, thereby reducing the inclusion of coarse particles in the organic acid. Organic acids contain functional groups [carboxy groups (—COOH), sulfonic acid groups (—SOH), thiol groups (—SH), and / or hydroxy groups (—OH)] in their molecules. By adjusting the particle size of the organic acid to the above range, the amount of these functional groups present in the organic acid is adjusted, imparting an excellent virus infection inhibitory effect to the virus infection inhibitor while reducing whitening due to crystallization of the organic acid caused by interactions between the functional groups of the organic acid.

[0049] The D50 particle size of the particulate organic acid is preferably 0.5 μm or more, more preferably 1 μm or more, more preferably 1.5 μm or more, and more preferably 2.0 μm or more. The D50 particle size of the particulate organic acid is preferably 14 μm or less, more preferably 12 μm or less, and more preferably 11 μm or less.

[0050] In the particulate organic acid, by setting the D50 particle size within the above-mentioned range (preferably, 0.5 to 14 μm) and the D90 particle size to 2 to 25 μm, the inclusion of coarse particles having particle sizes significantly different from the D50 particle size in the organic acid can be reduced, and the particle size of the organic acid can be made more appropriate.

[0051] By adjusting the particle size of the organic acid to a more appropriate range, the amount of the functional groups present on the surface of the organic acid can be more appropriately adjusted, more effectively imparting an excellent viral infection inhibitory effect to the viral infection inhibitor, and more effectively reducing whitening due to crystallization of the organic acid caused by interactions between the functional groups of the organic acid.

[0052] The D90 particle size and D50 particle size of an organic acid refer to the particle sizes (90% cumulative particle size and 50% cumulative particle size) at which the cumulative frequency (cumulative from particles with small particle sizes) in a volume-based particle size distribution measured by a laser scattering method is 90% and 50%, respectively. When the organic acid contains multiple types of organic acids, the D90 particle size and D50 particle size of the organic acid are values ​​measured based on the entire organic acid.

[0053] The organic acid is preferably solid at 1 atmosphere (1013.25 hPa) and 25° C. If the organic acid is solid at 1 atmosphere and 25° C., it will be more likely to appear on the surface of the virus infection-preventing product, such as a processed coating film, and will be more likely to come into contact with viruses, improving the virus infection-preventing effect.

[0054] In the viral infection inhibitor, the content of the organic acid is preferably 5 parts by mass or more, more preferably 10 parts by mass or more, and even more preferably 20 parts by mass or more, relative to 100 parts by mass of the compound having a salt of a sulfonic acid group. When the content of the organic acid is 5 parts by mass or more, it is possible to more reliably maintain or promote the liberation of a salt of a portion of the sulfonic acid group in the compound having a salt of a sulfonic acid group, and it is possible to further improve the viral infection inhibitory effect against enveloped viruses and non-enveloped viruses.

[0055] In the viral infection inhibitor, the content of the organic acid is preferably 8,000 parts by mass or less, more preferably 6,000 parts by mass or less, and even more preferably 4,000 parts by mass or less, relative to 100 parts by mass of the compound having a salt of a sulfonic acid group. When the content of the organic acid is 8,000 parts by mass or less, the synergistic effect of the compound having a salt of a sulfonic acid group and the organic acid can be further improved, thereby further improving the viral infection inhibitory effect against enveloped viruses and non-enveloped viruses.

[0056] [Virus infection inhibitor] The virus infection inhibitor contains a compound having a salt of a sulfonic acid group and an organic acid (excluding compounds having a sulfonic acid group) as active ingredients. The method for producing the virus infection inhibitor is not particularly limited, and the virus infection inhibitor can be produced by uniformly mixing the compound having a salt of a sulfonic acid group and the organic acid (excluding compounds having a sulfonic acid group) in a general manner.

[0057] The viral infection inhibitory effect refers to the effect of eliminating or reducing the infectivity of viruses to cells, or preventing them from replicating in the cells even if they infect. Examples of methods for confirming the presence or absence of such viral infectivity include ISO 18184 and JIS L1922 for textile products, and ISO 21702 for plastics and non-porous surface products other than textile products. The Society of International Antimicrobial Association (SIAA) certifies the antiviral finish mark to products that meet the safety and antiviral effect standards of antiviral finishing agents. The standard for antiviral effect is a difference (antiviral activity value) of 2.0 or more between the common logarithm of the viral infectivity of a blank product (product without antiviral finishing agent) and the common logarithm of the viral infectivity of a processed product (product with antiviral finishing agent added) in the ISO 21702 evaluation. The viral infection inhibitor is used as a component of the antiviral finishing agent, kneaded into resins, or added to surface coating agents such as paints, and evaluated using the above evaluation method.

[0058] In the present invention, when the viral infection inhibitory effect is evaluated under the following conditions, for example, a product is defined as a viral infection inhibitor if the difference in the common logarithm of the viral infectivity between a blank product and a processed product (antiviral activity value) is 2.0 or more. Regardless of the type of virus being evaluated, a product with a difference in the common logarithm of the viral infectivity between a blank product and a processed product (antiviral activity value) of 2.0 or more for at least one type of virus is treated as a viral infection inhibitor.

[0059] 50 mg of the virus infection inhibitor was added to 950 mg of a solvent-free ultraviolet-curable acrylic resin (manufactured by Hitachi Chemical Co., Ltd. under the trade name "Teslac 2328") and mixed uniformly to prepare a paint. The resulting paint was applied to a polyester film, and then irradiated with a dose of 512 mJ / cm using a UV conveyor device, iGrantage [manufactured by iGraphics Co., Ltd., irradiator reflector: cold mirror condenser type, UV lamp: H03-L31 (emission length: 250 mm)]. 2 The ultraviolet-curable acrylic resin is cured by applying ultraviolet light of 1000 kJ / cm to form a coating film having a thickness of 15 μm, which is used as a test coating film.

[0060] The obtained test coating film is subjected to an antiviral test in accordance with ISO 21702. The virus infectivity of the test coating film is calculated by the plaque method for the virus suspension after the reaction. A blank coating film is prepared in the same manner as above except that no virus infection inhibitor is added, and the virus infectivity (common logarithm) (PFU / cm) is calculated based on this blank coating film in the same manner as above. 2 The difference in common logarithm of the virus infectivity titers (antiviral activity value) is calculated by subtracting the virus infectivity titer of the test coating film from the virus infectivity titer of the blank coating film.

[0061] Other examples include the plaque method and hemagglutination unit (HAU) assay described in "Medical and Pharmaceutical Virology" (first published in April 1990).

[0062] The viral infection inhibitor has a viral infection inhibitory effect against various viruses due to the synergistic effect of a compound having a salt of a sulfonic acid group and an organic acid (excluding compounds having a sulfonic acid group), and exhibits excellent viral infection inhibitory effect against both enveloped and non-enveloped viruses.

[0063] Examples of enveloped viruses include influenza viruses (e.g., types A and B), rubella viruses, Ebola viruses, coronaviruses (e.g., SARS virus, novel coronavirus (SARS-CoV-2)), measles viruses, varicella-zoster viruses, herpes simplex viruses, mumps viruses, arboviruses, respiratory syncytial viruses, hepatitis viruses (e.g., hepatitis B virus, hepatitis C virus), yellow fever viruses, AIDS viruses, rabies viruses, hantaviruses, dengue viruses, Nipah viruses, and lyssaviruses.

[0064] Examples of non-enveloped viruses include adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, poliovirus, and rhinovirus.

[0065] The virus infection inhibitor is preferably used by having the compound having a salt of a sulfonic acid group or the organic acid that constitutes it present on the surface of resin particles.The virus infection inhibitor is preferably used by having the compound having a salt of a sulfonic acid group or the organic acid that constitutes it attached (supported) to the surface of resin particles.More preferably, the virus infection inhibitor is used by having the compound having a salt of a sulfonic acid group and the organic acid that constitutes it attached (supported) to the surface of particles.By having the compound having a salt of a sulfonic acid group or the organic acid that constitutes the virus infection inhibitor attached to at least the surface of the particles, the virus infection inhibitor can be uniformly dispersed in the substrate described below without forming clumps.Therefore, the surface area of ​​the virus infection inhibitor can be increased, sufficient contact between the virus infection inhibitor and the virus can be ensured, and the virus infection inhibitor's virus infection inhibitor effect can be fully exerted.

[0066] The particles to which a virus infection inhibitor, a compound having a salt of a sulfonic acid group, or an organic acid adheres to their surface are not particularly limited, as long as they do not inhibit the virus infection inhibitory effect of the virus infection inhibitor. Resin particles and inorganic particles are preferred as particles to which a virus infection inhibitor, a compound having a salt of a sulfonic acid group, or an organic acid adheres to their surface. Examples of synthetic resins constituting the resin particles include styrene-based resins, acrylic-based resins, urethane-based resins, vinyl chloride-based resins, ABS resins, and synthetic rubbers such as styrene-butadiene rubber (SBR) and nitrile-butadiene rubber (NBR). Preferably, the resin contains an acrylic resin or a styrene-based resin, more preferably a styrene-based resin, and more preferably polystyrene. The synthetic resins may be used alone or in combination of two or more.

[0067] The content of the acrylic resin in the resin particles is preferably 50% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, and more preferably 100% by mass or more.

[0068] The content of the styrene-based resin in the resin particles is preferably 50% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, and more preferably 100% by mass or more.

[0069] The styrene-based resin is not particularly limited, and examples thereof include homopolymers or copolymers containing, as monomer units, styrene-based monomers such as styrene, methylstyrene, ethylstyrene, i-propylstyrene, dimethylstyrene, chlorostyrene, and bromostyrene, and copolymers containing, as monomer units, a styrene-based monomer and one or more vinyl monomers copolymerizable with the styrene-based monomer.

[0070] Examples of vinyl monomers copolymerizable with styrene-based monomers include acrylic monomers such as acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, acrylic acid esters (methyl acrylate, ethyl acrylate, butyl acrylate, etc.), methacrylic acid esters (methyl methacrylate, ethyl methacrylate, butyl methacrylate, etc.), maleic anhydride, and acrylamide.

[0071] The synthetic resin constituting the resin particles preferably contains an aromatic ring, which attracts the hydrophobic moiety of the compound having a salt of a sulfonic acid group attached to the surface of the resin particles and orients the hydrophilic salt of the sulfonic acid group outward, thereby enabling the virus infection inhibitor to more effectively exert its virus infection inhibitory effect.

[0072] The inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include silica, silica gel, zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, magnesium hydroxide, diatomaceous earth, kaolin, talc, aluminum hydroxide, titanium oxide, calcium phosphate, calcium sulfate, magnesium carbonate, zinc oxide, manganese oxide, iron oxide, aluminum oxide, barium sulfate, zirconium oxide, tungsten oxide, zirconium phosphate, zirconium carbide, glass, calcium silicate, aluminum silicate, silicon carbide, activated carbon, tobermorite, montmorillonite, bentonite, iron, tin, aluminum, zinc, copper, titanium, nickel, various alloys, etc. The inorganic materials may be used alone or in combination of two or more.

[0073] The D50 particle size of the particles is preferably 0.1 μm or more, more preferably 1 μm or more. The D50 particle size of the particles is preferably 30 μm or less, more preferably 15 μm or less. When the D50 particle size of the particles is 0.1 μm or more, the surface area of ​​the particles is reduced, the agglomeration of the virus infection inhibitor is reduced, and the virus infection inhibitor and the virus interact more easily, improving the virus infection inhibitory effect. When the D50 particle size of the particles is 30 μm or less, aggregation of the virus infection inhibitor is prevented and the surface area is increased, facilitating contact with the virus, improving the virus infection inhibitory effect of the virus infection inhibitor.

[0074] The D50 particle size of each particle refers to the particle size (50% cumulative particle size) at which the cumulative frequency (cumulative from particles with small particle sizes) in the volume-based particle size distribution measured by a laser scattering method is 50%. When the particles contain multiple types of particles, the D50 particle size of the particles is a value measured based on the entire particles.

[0075] The amount of the virus infection inhibitor attached to the resin particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and even more preferably 10 parts by mass or more, per 100 parts by mass of the resin particles. When the amount of the virus infection inhibitor attached is 1 part by mass or more, the virus infection inhibitor can be uniformly attached to the surface of the resin particles, and the virus infection inhibitor's effect of inhibiting virus infection can be more effectively exerted.

[0076] The amount of the virus infection inhibitor attached to the resin particles is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and still more preferably 20 parts by mass or less, per 100 parts by mass of the resin particles. When the amount of the virus infection inhibitor attached is 50 parts by mass or less, the virus infection inhibitor does not bond to itself, and the virus infection inhibitor is efficiently distributed on the surface of the resin particles, improving the virus infection prevention effect.

[0077] The amount of the compound having a salt of a sulfonic acid group attached to the resin particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and even more preferably 10 parts by mass or more, per 100 parts by mass of the resin particles. When the amount of the compound having a salt of a sulfonic acid group attached is 1 part by mass or more, the compound having a salt of a sulfonic acid group can be uniformly attached to the surface of the resin particles, and the virus infection inhibitor can more effectively exhibit its virus infection inhibitory effect.

[0078] The amount of the compound having a salt of a sulfonic acid group attached to the resin particles is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and still more preferably 20 parts by mass or less, per 100 parts by mass of the resin particles. When the amount of the compound having a salt of a sulfonic acid group attached is 50 parts by mass or less, bonding between compounds having a salt of a sulfonic acid group is not performed, and the compound having a salt of a sulfonic acid group is efficiently arranged on the surface of the resin particles, thereby improving the viral infection prevention effect.

[0079] The manner in which the virus infection inhibitor, the compound having a salt of a sulfonic acid group, or the organic acid is attached to the surface of the resin particles is not particularly limited, and may be, for example, by relying on the adhesive strength of the virus infection inhibitor, the compound having a salt of a sulfonic acid group, or the organic acid itself, or by using a binder resin to adhere the virus infection inhibitor, the compound having a salt of a sulfonic acid group, or the organic acid to the surface of the resin particles. However, since this allows the virus infection inhibitor to effectively exert its virus infection inhibitory effect, it is preferable that the virus infection inhibitor be attached to the surface of the resin particles by the adhesive strength of the compound having a salt of a sulfonic acid group contained in the virus infection inhibitor itself.

[0080] The virus infection inhibitor is used by being contained in a base material to which it is desired to impart a virus infection inhibitory effect, and the base material containing the virus infection inhibitor exhibits a virus infection inhibitory effect as a virus infection inhibitory product.

[0081] The substrate to be incorporated with the virus infection inhibitor is not particularly limited as long as it is capable of incorporating the virus infection inhibitor, and examples include synthetic resin molded products, paints, wallpaper, decorative sheets, flooring materials, textile products (woven fabrics, nonwoven fabrics, knitted fabrics), interior and interior materials for vehicles (for example, cars, airplanes, ships, etc.) (seats, child seats, and foams that constitute these), kitchenware, baby products, and building interior materials.

[0082] As the paint, conventionally known paints are used, and examples thereof include oil-based paints (e.g., mixed paints, oil varnishes, etc.), cellulose paints, synthetic resin paints, etc. The paint may contain additives such as pigments, plasticizers, hardeners, extenders, fillers, antioxidants, tackifiers, surfactants, etc., within the scope of not impairing its physical properties. Incidentally, examples of methods for incorporating the virus infection inhibitor into the paint include a method in which the virus infection inhibitor and the paint are supplied to a dispersing device and uniformly mixed. Incidentally, examples of dispersing devices include a high-speed mill, a ball mill, and a sand mill.

[0083] The building interior materials are not particularly limited, and examples thereof include flooring materials, wallpaper, ceiling materials, paints, doorknobs, switches, switch covers, wax, and the like.

[0084] The vehicle interior goods and materials are not particularly limited, and examples thereof include seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trim, instrument panels, consoles, glove boxes, handrails, and the like.

[0085] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.

[0086] [Preparation of Carboxy Group-Containing Compounds 1 to 5] An acrylic monomer solution was obtained by mixing the predetermined amounts of acrylic acid and methyl acrylate shown in Table 1. A predetermined amount of 1-hydroxycyclohexan-1-yl phenyl ketone (manufactured by IGM Resins B.V., trade name "Omnirad 184") as a radical polymerization initiator shown in Table 1 was added to the obtained acrylic monomer solution and dissolved, thereby preparing a raw material composition.

[0087] The raw material composition was applied to a polyethylene film using a wire bar coater #14 to form a coating layer with a thickness of 35 μm. Using a UV conveyor device (manufactured by Eye Graphics Co., Ltd., product name "ECS301G1"), ultraviolet light with a wavelength of 365 nm was applied to the coating layer at 25° C. with an integrated light intensity of 2000 mJ / cm. 2 Radical polymerization was carried out by irradiating the solution so that the temperature was such ...

[0088]

[0089] [Preparation of Organic Acid Particles] The organic acids shown in Table 2 were coarsely pulverized using a roll press (Seishin Enterprise Co., Ltd., trade name "150 type") at a rotation speed of 25 rpm and a pressing force of 25 tons, and then pulverized using a jet mill (Nisshin Engineering Inc., trade name "SJ-500") at a supply rate and compressed air pressure of 0.75 MPa shown in Table 2 to obtain organic acid particles. Note that oleic acid could not be granulated because its melting point is below room temperature (25°C).

[0090] [Preparation of Resin Particles Having Particles of Carboxy Group-Containing Compound 2 Adhered to Their Surfaces] 5 parts by mass of particles of the carboxy group-containing compound 2 and 10 parts by mass of polystyrene particles (primary particles) having a D50 particle size of 4 μm were supplied to 100 parts by mass of water, and powdered using a spray dryer at an atomizer rotation speed of 20,000 rpm. The entire amount of particles of the carboxy group-containing compound 2 was adhered (supported) to the surfaces of the polystyrene particles, and then pulverized using a jet mill (manufactured by Nisshin Engineering Inc., trade name "SJ-500") under operating conditions of a raw material supply rate of 1 kg / h and a compressed air pressure of 0.75 MPa, to obtain resin particles having particles of the carboxy group-containing compound 2 adhered to their surfaces. In Table 2, "resin particles having particles of the carboxy group-containing compound 2 adhered to their surfaces" are referred to as "resin particle-adhered carboxy group-containing compound 2."

[0091] [Preparation of inorganic particles having particles of carboxy group-containing compound 2 adhered to their surfaces] 5 parts by mass of particles of carboxy group-containing compound 2 and 10 parts by mass of silica particles (primary particles) having a D50 particle size of 6 μm were supplied to 100 parts by mass of water, and powdered using a spray dryer at an atomizer rotation speed of 20,000 rpm. The entire amount of particles of carboxy group-containing compound 2 was adhered (supported) to the surfaces of the silica particles, and then pulverized using a jet mill (manufactured by Nisshin Engineering Inc., trade name "SJ-500") under operating conditions of a raw material supply rate of 1 kg / h and a compressed air pressure of 0.75 MPa, to obtain silica particles having particles of carboxy group-containing compound 2 adhered to their surfaces. In Table 2, "silica particles having particles of carboxy group-containing compound 2 adhered to their surfaces" is referred to as "inorganic particle-adhered carboxy group-containing compound 2."

[0092] (Examples 1 to 11, 16 to 20 and Comparative Example 1) A virus infection inhibitor was prepared by uniformly mixing 100 parts by mass of a salt compound shown in Table 2 with 900 parts by mass of organic acid particles shown in Table 2. Note that oleic acid was used without being granulated because its melting point was below room temperature (25°C).

[0093] Examples 12 to 15 50 parts by mass of a salt compound shown in Table 2 and 150 parts by mass of polystyrene particles (primary particles) having a D50 particle size of 4 μm were supplied to 800 parts by mass of water and powdered using a spray dryer (atomizer rotation speed: 20,000 rpm), so that the entire amount of the salt compound was adhered (supported) to the surfaces of the polystyrene particles. 100 parts by mass of the polystyrene particles to which the salt compound was adhered (supported) and 900 parts by mass of particles of an organic acid shown in Table 2 were uniformly mixed to prepare a virus infection inhibitor.

[0094] Example 21 A virus infection inhibitor was prepared by uniformly mixing 100 parts by mass of the salt compound shown in Table 2 and 900 parts by mass of the resin particle-adhered carboxy group-containing compound 2 shown in Table 2.

[0095] Example 22 A viral infection inhibitor was prepared by uniformly mixing 100 parts by mass of the salt compound shown in Table 2 and 900 parts by mass of inorganic particle-attached carboxy group-containing compound 2 particles shown in Table 2.

[0096] Comparative Example 2 100 parts by mass of sodium dodecylbenzenesulfonate was used as a virus infection inhibitor.

[0097] Comparative Example 3 100 parts by mass of adipic acid particles were used as a virus infection inhibitor.

[0098] The obtained viral infection inhibitor was subjected to an antiviral test using influenza virus (enveloped virus) and feline calicivirus (non-enveloped virus). The results are shown in Table 3.

[0099] For the organic acids contained in the virus infection inhibitor, the melting point at 1 atmosphere, solubility in water at 25°C, pKa at 25°C, molecular weight (weight average molecular weight in the case of polymers), D90 particle size, and D50 particle size are shown in Table 2. In Table 2, "melting point at 1 atmosphere" and "solubility in water at 25°C" are simply referred to as "melting point" and "solubility."

[0100] (Antiviral test) 50 mg of the virus infection inhibitor was added to 950 mg of a solvent-free ultraviolet-curable acrylic resin (trade name "Teslac 2328" manufactured by Hitachi Chemical Co., Ltd.) and mixed uniformly to prepare a paint. The resulting paint was applied to a polyester film, and then irradiated with a dose of 512 mJ / cm using a UV conveyor device, iGrantage [manufactured by iGraphics Co., Ltd., irradiator reflector: cold mirror condensing type, UV lamp: H03-L31 (emission length 250 mm)]. 2 The ultraviolet-curable acrylic resin was cured by applying ultraviolet light of 1000 W to form a coating film with a thickness of 15 μm. When the virus infection inhibitor was attached (supported) to polystyrene particles or silica particles, the amount of the virus infection inhibitor was adjusted to 50 mg.

[0101] The surface of the obtained coating film was soaked in 1 mL of water onto a flat square nonwoven fabric (manufactured by Nippon Paper Crecia Co., Ltd., product name "Kimwipe S-200") with each side being 10 cm long, and the coating film surface was wiped with the nonwoven fabric by moving it back and forth 10 times to obtain a test coating film.

[0102] The obtained test coating film was subjected to an antiviral test in accordance with ISO 21702. The virus infectivity of the test coating film was calculated by the plaque method for the virus suspension after the reaction.

[0103] A blank coating film was prepared in the same manner as above, except that no virus infection inhibitor was added, and the virus infectivity (common logarithm) (PFU / cm) was calculated based on this blank coating film in the same manner as above. 2 The virus infectivity titer (common logarithm) of the blank coating film was calculated as 6.5 PFU / cm 2 It was.

[0104] The antiviral activity value was calculated by subtracting the viral infectivity of the test coating from the viral infectivity of the blank coating.

[0105] In the antiviral tests conducted in the examples, the surface of the coating film was wiped with a nonwoven fabric soaked in water in the method for measuring the viral infectivity titer described in the "Mode for Carrying Out the Invention." The coating film after wiping was used as the test coating film.

[0106] Wiping the surface of the coating film with the nonwoven fabric reduces the viral infection-inhibiting effect of the coating film. That is, in the examples, the virus test is conducted under stricter conditions. The antiviral activity values ​​obtained in the examples are lower than the antiviral activity values ​​obtained by the measurement method described in the "Mode for Carrying Out the Invention." Therefore, when the antiviral activity value obtained in the antiviral test of the examples is 2 or more, it can be determined that the viral infection inhibitor has a viral infection-inhibiting effect.

[0107] (Haze Value) Test coating films were prepared in the same manner as in the antiviral test. The haze of the obtained test coating films was evaluated in accordance with JIS K 7361. The haze value (%) was measured using a haze meter (manufactured by Murakami Color Research Laboratory Co., Ltd., product name "HM-150") in an environment of room temperature 25°C and relative humidity 40%.

[0108]

[0109]

[0110] The viral infection inhibitor of the present invention contains a compound having a salt of a sulfonic acid group and an organic acid, and therefore has an excellent viral infection inhibitory effect against both enveloped and non-enveloped viruses, and exhibits a viral infection inhibitory effect against various types of viruses.

[0111] By incorporating the virus infection inhibitor of the present invention into a substrate, an excellent virus infection inhibitory effect can be imparted to the substrate.

[0112] (Cross-reference to related applications) This application claims priority based on Japanese Patent Application No. 2021-040825, filed on March 12, 2021, the disclosure of which is incorporated herein by reference in its entirety.

Claims

1. A viral infection inhibitor comprising a compound having a salt of a sulfonic acid group and an organic acid.

2. The virus infection inhibitor according to claim 1, characterized in that the organic acid has a solubility in water at 25°C of 20 g / L or less.

3. A viral infection inhibitor as described in claim 1 or 2, characterized in that the organic acid has a carboxy group.

4. A viral infection inhibitor described in any one of claims 1 to 3, characterized in that the organic acid has a pKa of 5.5 or less at 25°C.

5. A viral infection inhibitor described in any one of claims 1 to 3, characterized in that the organic acid has a pKa of 4.6 or less at 25°C.

6. A virus infection inhibitor according to any one of claims 1 to 5, characterized in that the organic acid is a polymer and has a weight-average molecular weight of 3,000 or more.

7. A virus infection inhibitor according to any one of claims 1 to 6, characterized in that the organic acid is in particulate form and has a D90 particle size of 2 to 25 μm.

8. A viral infection inhibitor according to any one of claims 1 to 7, characterized in that the compound having a salt of a sulfonic acid group has an aromatic ring.

9. A virus infection inhibitor described in any one of claims 1 to 8, characterized in that the compound having a salt of a sulfonic acid group or the organic acid is present on the surface of the particles.

10. A virus infection inhibitor described in any one of claims 1 to 8, characterized in that the compound having a salt of a sulfonic acid group or the organic acid is attached to the surface of the particles.

11. A virus infection inhibitor according to claim 9 or 10, characterized in that the particles are resin particles or inorganic particles.

12. The virus infection inhibitor according to claim 11, characterized in that the resin particles contain an acrylic resin or a styrene resin.

13. A virus infection-preventing product comprising: a base material; and a virus infection-preventing agent according to any one of claims 1 to 13 contained in the base material.